SAMANTHA GAUVIN: Open Payments
NPI 1144902636 · CEDAR BLUFF, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,348 in 66 payments from 8 companies in 2025. Trend: 2023 $76 · 2024 $1,331 · 2025 $1,348
Food & beverage: $1,272Education: $76
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 13 | $288 |
| E.R. Squibb & Sons, L.L.C. | 10 | $273 |
| Teva Pharmaceuticals USA, Inc. | 15 | $260 |
| ABBVIE INC. | 14 | $145 |
| Janssen Pharmaceuticals, Inc | 7 | $144 |
| Otsuka America Pharmaceutical, Inc. | 2 | $137 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $70 |
| Alkermes, Inc. | 2 | $31 |
Products named: INGREZZA, COBENFY, AUSTEDO XR, VRAYLAR, REXULTI, INVEGA SUSTENNA, CAPLYTA, ARISTADA.
Industry payments across VA — which companies pay providers there.
